ABOUT BIOMARIN
Founded 25 years ago, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery.
Learn More about BioMarin ⌃CAREERS AT BIOMARIN
Our focus on genetic disease gives us the opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
View Now ⌃-
November 23, 2022BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
-
November 7, 2022BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
-
November 3, 2022BioMarin to Participate in Two Upcoming Investor Conferences
-
October 26, 2022BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
-
October 12, 2022FDA Accepts BioMarin’s Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
-
October 6, 2022BioMarin Simplifies Organizational Structure to Increase Efficiency
-
October 4, 2022BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET
-
September 29, 2022BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA